简述将药用脂质体开发为纳米级肠外给药系统的质量设计方法

Prachi Atre and Syed A. A. Rizvi
{"title":"简述将药用脂质体开发为纳米级肠外给药系统的质量设计方法","authors":"Prachi Atre and Syed A. A. Rizvi","doi":"10.1039/D4PM00201F","DOIUrl":null,"url":null,"abstract":"<p >Liposomes are sophisticated drug delivery vehicles that have significantly broadened the range of therapeutic agents that can be selectively delivered along with controlled release. Liposomes are small vesicles (size optimizable) composed of a lipid bilayer that encapsulates hydrophilic as well as hydrophobic drugs. This advancement has led to the creation of liposomal nano-formulations for drugs with very poor water solubility and cell membrane permeability, resulting in improved therapeutic efficacy and reduced side effects. Liposomal formulations can also be engineered with ligands or antibodies to target specific cells or tissues, ensuring site-specific drug delivery and minimizing off-target side effects. These targeted liposomal formulations have shown promising potential in treating various diseases, such as cancer, infectious diseases, and inflammatory disorders. With continuous advancements in liposomal technology, researchers are exploring new ways to further optimize the liposomal formulations for enhanced drug stability, bioavailability, and targeted delivery to specific cells or tissues. The Quality by Design (QbD) approach is a systematic and scientific method for designing and developing pharmaceutical products, ensuring quality and consistency throughout the product lifecycle. Applied to the development of pharmaceutical liposomes, QbD facilitates the optimization of liposome formulations for targeted drug delivery, improved stability, and enhanced therapeutic outcomes. The creation of novel liposomal formulations with superior drug stability, bioavailability, and targeting capabilities will undoubtedly play a crucial role in shaping the future of medicine and improving patient care. This brief review provides an overview of the development of liposomes as nanocarrier systems for parenteral drug delivery, covering aspects such as quality manufacturing attributes, structure, preparation methods, characterization, clinical applications, and regulatory considerations.</p>","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 4","pages":" 675-688"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2024/pm/d4pm00201f?page=search","citationCount":"0","resultStr":"{\"title\":\"A brief overview of quality by design approach for developing pharmaceutical liposomes as nano-sized parenteral drug delivery systems\",\"authors\":\"Prachi Atre and Syed A. A. Rizvi\",\"doi\":\"10.1039/D4PM00201F\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >Liposomes are sophisticated drug delivery vehicles that have significantly broadened the range of therapeutic agents that can be selectively delivered along with controlled release. Liposomes are small vesicles (size optimizable) composed of a lipid bilayer that encapsulates hydrophilic as well as hydrophobic drugs. This advancement has led to the creation of liposomal nano-formulations for drugs with very poor water solubility and cell membrane permeability, resulting in improved therapeutic efficacy and reduced side effects. Liposomal formulations can also be engineered with ligands or antibodies to target specific cells or tissues, ensuring site-specific drug delivery and minimizing off-target side effects. These targeted liposomal formulations have shown promising potential in treating various diseases, such as cancer, infectious diseases, and inflammatory disorders. With continuous advancements in liposomal technology, researchers are exploring new ways to further optimize the liposomal formulations for enhanced drug stability, bioavailability, and targeted delivery to specific cells or tissues. The Quality by Design (QbD) approach is a systematic and scientific method for designing and developing pharmaceutical products, ensuring quality and consistency throughout the product lifecycle. Applied to the development of pharmaceutical liposomes, QbD facilitates the optimization of liposome formulations for targeted drug delivery, improved stability, and enhanced therapeutic outcomes. The creation of novel liposomal formulations with superior drug stability, bioavailability, and targeting capabilities will undoubtedly play a crucial role in shaping the future of medicine and improving patient care. This brief review provides an overview of the development of liposomes as nanocarrier systems for parenteral drug delivery, covering aspects such as quality manufacturing attributes, structure, preparation methods, characterization, clinical applications, and regulatory considerations.</p>\",\"PeriodicalId\":101141,\"journal\":{\"name\":\"RSC Pharmaceutics\",\"volume\":\" 4\",\"pages\":\" 675-688\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://pubs.rsc.org/en/content/articlepdf/2024/pm/d4pm00201f?page=search\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"RSC Pharmaceutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://pubs.rsc.org/en/content/articlelanding/2024/pm/d4pm00201f\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"RSC Pharmaceutics","FirstCategoryId":"1085","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2024/pm/d4pm00201f","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

脂质体是一种先进的给药载体,它大大拓宽了可选择性给药和控释的治疗药物范围。脂质体是由脂质双分子层组成的小囊泡(大小可优化),可包裹亲水性和疏水性药物。这一进步促使人们开发出纳米脂质体制剂,用于治疗水溶性和细胞膜渗透性极差的药物,从而提高了疗效,减少了副作用。脂质体制剂还可与配体或抗体一起设计,以特定细胞或组织为靶点,确保特定部位给药,最大限度地减少脱靶副作用。这些靶向脂质体制剂在治疗癌症、传染病和炎症性疾病等各种疾病方面显示出巨大的潜力。随着脂质体技术的不断进步,研究人员正在探索进一步优化脂质体制剂的新方法,以提高药物的稳定性、生物利用度以及对特定细胞或组织的靶向递送。质量源于设计(QbD)方法是一种设计和开发药品的系统化科学方法,可确保整个产品生命周期的质量和一致性。将 QbD 应用于药用脂质体的开发,有助于优化脂质体制剂,实现靶向给药、提高稳定性并增强治疗效果。新型脂质体制剂具有卓越的药物稳定性、生物利用度和靶向能力,无疑将在塑造未来医学和改善患者护理方面发挥至关重要的作用。本综述概述了脂质体作为用于肠外给药的纳米载体系统的发展情况,涉及质量生产属性、结构、制备方法、表征、临床应用和监管注意事项等方面。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

A brief overview of quality by design approach for developing pharmaceutical liposomes as nano-sized parenteral drug delivery systems

A brief overview of quality by design approach for developing pharmaceutical liposomes as nano-sized parenteral drug delivery systems

Liposomes are sophisticated drug delivery vehicles that have significantly broadened the range of therapeutic agents that can be selectively delivered along with controlled release. Liposomes are small vesicles (size optimizable) composed of a lipid bilayer that encapsulates hydrophilic as well as hydrophobic drugs. This advancement has led to the creation of liposomal nano-formulations for drugs with very poor water solubility and cell membrane permeability, resulting in improved therapeutic efficacy and reduced side effects. Liposomal formulations can also be engineered with ligands or antibodies to target specific cells or tissues, ensuring site-specific drug delivery and minimizing off-target side effects. These targeted liposomal formulations have shown promising potential in treating various diseases, such as cancer, infectious diseases, and inflammatory disorders. With continuous advancements in liposomal technology, researchers are exploring new ways to further optimize the liposomal formulations for enhanced drug stability, bioavailability, and targeted delivery to specific cells or tissues. The Quality by Design (QbD) approach is a systematic and scientific method for designing and developing pharmaceutical products, ensuring quality and consistency throughout the product lifecycle. Applied to the development of pharmaceutical liposomes, QbD facilitates the optimization of liposome formulations for targeted drug delivery, improved stability, and enhanced therapeutic outcomes. The creation of novel liposomal formulations with superior drug stability, bioavailability, and targeting capabilities will undoubtedly play a crucial role in shaping the future of medicine and improving patient care. This brief review provides an overview of the development of liposomes as nanocarrier systems for parenteral drug delivery, covering aspects such as quality manufacturing attributes, structure, preparation methods, characterization, clinical applications, and regulatory considerations.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信